https://pharmaphorum.com/r-d/breaking-into-the-global-pharmaceutical-market-rudacure/
RudaCure es una empresa biotecnológica de cuatro años based in the South Korea, focusing on ocular disease and dolor crónico with a pair of potentially first-in-class drugs. La empresa recently raised $16.5 million in Serie A financiamiento and has partnered with Hanlim Pharmaceuticals, a local pharma company, to develop and distribute its candidato a fármaco for Enfermedad de Ojo Seco.
La empresa recently incorporated in the US and is participating in a MassChallenge accelerator programame via a asociación between MassChallenge, Korea’s Bio I-Corps programame and the Korean Innovación Center in Washington. They’ve also begun attending US-based events like JP Morgan, to start to make the connections that will help them sell and develop their products on a global scale.
